Pfizer is buying Mylan in an all-stock deal and combining the $10bn generic pharmaceutical company with its own off-patent branded and generic business.

A claim that IBRC overcharged developer John Flynn €100,000 on loans has to be seen in the context of Nama’s claim Mr Flynn and his family owe the agency €21m, the Commercial Court has heard.